Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 – 2013)

AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53

(2013) Ondrej Kalous et al.   BREAST CANCER RESEARCH AND TREATMENT

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma

(2013) E Tavanti et al.   BRITISH JOURNAL OF CANCER

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

(2013) Hagop M. Kantarjian et al.   CANCER

Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase

(2013) Santhosh Palani et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells

(2013) Irena Horwacik et al.   CANCER LETTERS

A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis

(2013) James Foran et al.   Clinical Lymphoma Myeloma & Leukemia

Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer

(2013) Michel D Wissing et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors

(2013) E. Raymond et al.   INVESTIGATIONAL NEW DRUGS

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

(2013) S. F. Dent et al.   INVESTIGATIONAL NEW DRUGS

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2013) Kevin R. Kelly et al.   INVESTIGATIONAL NEW DRUGS

AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models

(2013) Tammy L. Bush et al.   MOLECULAR CANCER THERAPEUTICS

AURORA KINASES: STRUCTURE, FUNCTIONS AND THEIR ASSOCIATION WITH CANCER

(2012) Madhu Kollareddy et al.   BIOMEDICAL PAPERS-OLOMOUC

Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure

(2012) Hielke J. Meulenbeld et al.   BJU INTERNATIONAL

A Small-Molecule Inhibitor Targeting the Mitotic Spindle Checkpoint Impairs the Growth of Uterine Leiomyosarcoma

(2012) W. Shan et al.   CLINICAL CANCER RESEARCH

Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale

(2012) E. Komlodi-Pasztor et al.   CLINICAL CANCER RESEARCH

Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models

(2012) J. R. Diamond et al.   CLINICAL CANCER RESEARCH

Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model

(2012) K. Fraedrich et al.   CLINICAL CANCER RESEARCH

ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer

(2012) Ursula A. Matulonis et al.   EUROPEAN JOURNAL OF CANCER

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors

(2012) Gary K. Schwartz et al.   INVESTIGATIONAL NEW DRUGS

Aurora kinase inhibitors: Progress towards the clinic

(2012) Madhu Kollareddy et al.   INVESTIGATIONAL NEW DRUGS

Development of o-Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors

(2012) Harshani R. Lawrence et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cancer Cell Resistance to Aurora Kinase Inhibitors: Identification of Novel Targets for Cancer Therapy

(2012) Rita Hrabakova et al.   JOURNAL OF PROTEOME RESEARCH

MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia

(2012) F J Giles et al.   LEUKEMIA

Molecular dynamics and free energy studies on Aurora kinase A and its mutant bound with MLN8054: insight into molecular mechanism of subtype selectivity

(2012) Ying Yang et al.   Molecular BioSystems

Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)

(2012) Fei Fei et al.   Molecular Cancer

An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

(2012) K. E. Hook et al.   MOLECULAR CANCER THERAPEUTICS

In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma

(2012) Alexander Dewerth et al.   PEDIATRIC SURGERY INTERNATIONAL

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies

(2011) H.- T. Arkenau et al.   ANNALS OF ONCOLOGY

The potential role of Aurora kinase inhibitors in haematological malignancies

(2011) Sherif S. Farag   BRITISH JOURNAL OF HAEMATOLOGY

HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo

(2011) T. Nguyen et al.   CLINICAL CANCER RESEARCH

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours

(2011) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Update on aurora kinase targeted therapeutics in oncology

(2011) Myke R Green et al.   Expert Opinion on Drug Discovery

Aurora kinase inhibitor patents and agents in clinical testing: an update (2009 – 10)

(2011) Chun Hei Antonio Cheung et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

High Chromosome Number in hematological cancer cell lines is a Negative Predictor of Response to the inhibition of Aurora B and C by GSK1070916

(2011) Christopher Moy et al.   Journal of Translational Medicine

Shining the Light on Aurora-A Kinase as a Drug Target in Pancreatic Cancer

(2011) D. J. Bearss   MOLECULAR CANCER THERAPEUTICS

Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro

(2011) Stefan Balabanov et al.   PLoS One

In vitroandin vivopharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases

(2011) Liyue Huang et al.   XENOBIOTICA

Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

(2010) M. Payton et al.   CANCER RESEARCH

Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?

(2010) A. A. Dar et al.   MOLECULAR CANCER THERAPEUTICS

Aurora kinase A is a target of Wnt/ -catenin involved in multiple myeloma disease progression

(2009) J. Dutta-Simmons et al.   BLOOD

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation

(2009) Y. Shiotsu et al.   BLOOD

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

(2009) R. B. Cohen et al.   CLINICAL CANCER RESEARCH

Aurora kinase inhibitors in preclinical and clinical testing

(2009) Chun Hei Antonio Cheung et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Advances in Aurora kinase inhibitor patents

(2009) Mohane Selvaraj Coumar et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions

(2008) Altaf A. Dar et al.   CANCER

Linking Cell Cycle to Asymmetric Division: Aurora-A Phosphorylates the Par Complex to Regulate Numb Localization

(2008) Frederik Wirtz-Peitz et al.   CELL

Aurora Kinase Family: A New Target for Anticancer Drug

(2008) Teresa Macarulla et al.   Recent Patents on Anti-Cancer Drug Discovery